Luo J, Martucci VL, Quandt Z, Groha S, Murray MH, Lovly CM, Rizvi H, Egger JV, Plodkowski AJ, Abu-Akeel M, Schulze I, Merghoub T, Cardenas E, Huntsman S, Li M, Hu D, Gubens MA, Gusev A[+], Aldrich MC[+], Hellmann MD[+], Ziv E[+]. Clin Cancer Res. 2021
This study demonstrated a significant association across three cohorts between (a) germline risk for a complex phenotype (thyroid conditions and use of thyroid medication) in a non-cancer setting and (b) thyroid disfunction / adverse events brought on by immunotherapy in lung cancer patients. This work adds to a growing body of literature showing that cancer immunotherapy is influenced by common germline variation, and is a preview of how germline risk scores could be leveraged to understand the mechanisms of cancer outcomes more broadly.
Figure: Kaplan-Meier plot of time to thyroid adverse event stratified on germline risk score in two independent cohorts.